AB Science S.A. (OTCMKTS:ABSCF) Sees Large Increase in Short Interest

AB Science S.A. (OTCMKTS:ABSCF) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 961 shares, an increase of ∞ from the June 30th total of 0 shares. Based on an average daily trading volume, of 40 shares, the short-interest ratio is currently 24.0 days.

AB Science Price Performance

Shares of ABSCF opened at $1.12 on Friday. The company’s fifty day moving average is $1.12 and its two-hundred day moving average is $1.29. AB Science has a 1 year low of $1.12 and a 1 year high of $1.37.

AB Science Company Profile

AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.

Since its founding in 2001 by Dr.